Study of the impact of DPD activity on the efficacy of capecitabine

2024-517481-41-00 Protocol DPD MAX Phase I and Phase II (Integrated) - Other Ongoing, recruitment ended

Start 2 Oct 2024 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 4 sites · Protocol DPD MAX

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruitment ended
Participants planned 155
Countries 1
Sites 4

breast cancer

Key facts

Sponsor
Centre Antoine Lacassagne
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
2 Oct 2024 → ongoing
Decision date (initial)
2024-10-02
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517481-41-00
EudraCT number
2017-002037-31
ClinicalTrials.gov
NCT04198727

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

breast cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Antoine Lacassagne

Sponsor organisation
Centre Antoine Lacassagne
Address
33 Avenue De Valombrose
City
Nice Cedex 2
Postcode
06189
Country
France

Scientific contact point

Organisation
Centre Antoine Lacassagne
Contact name
Dr Anne CREISSON

Public contact point

Organisation
Centre Antoine Lacassagne
Contact name
Dr Anne CREISSON

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 155 4
Rest of world 0

Investigational sites

France

4 sites · Ongoing, recruitment ended
Polyclinique Saint George
Medical Oncology, 2 avenue de Rimiez, 06105, NICE
Centre azureen de cancerologie
Oncology, 1 Place Du Docteur Jean Luc Broquerie, 06250, Mougins
Centre Antoine Lacassagne
Oncology, 33 Avenue De Valombrose, 06189, Nice Cedex 2
Centre Hospitalier D'Antibes Juan Les Pins
Oncology, 107 Avenue De Nice, 06606, Antibes Cedex

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-10-02 2024-10-02 2025-02-28

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-13 France Acceptable
2024-09-27
2024-10-02
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-05 France Acceptable
2024-12-30
2024-12-30
3 SUBSTANTIAL MODIFICATION SM-2 2026-03-17 France Acceptable
2026-04-07
2026-04-23